Kelly Underhill
Papers
2
Total Citations
34
H-Index
2
About
Dr. Kelly Underhill is a leading clinical researcher in radiation oncology, with a focused expertise in stereotactic body radiotherapy (SBRT) for prostate cancer. Her work is pivotal in advancing patient-specific, dose-escalated treatments that optimize both tumor control and quality of life. Dr. Underhill’s major contributions include landmark analyses from multi-institutional Phase II trials, where she demonstrated that heterogeneous dosing SBRT yields excellent 5-year outcomes for low- and intermediate-risk prostate cancer, with 90% of patients treated in community settings—proving the regimen’s real-world applicability. Her secondary analysis of patient and dosimetric predictors, cited 25 times, is a key resource for clinicians, revealing how specific dose constraints and baseline urinary function directly impact genitourinary and bowel quality of life. By bridging rigorous dosimetric data with patient-reported outcomes, Dr. Underhill has helped refine SBRT delivery to minimize toxicity. Her work, encompassing 259 patients across 14 institutions, provides the long-term evidence needed to solidify SBRT as a standard-of-care option. For students and researchers, Dr. Underhill’s research exemplifies how thoughtful trial design and patient-centered endpoints can transform emerging technologies into durable, life-improving therapies.
Research Focus
Key Achievements
Top Papers
- 1
- 2